LETROZOLE AND RIBOCICLIB (KISQALI FEMARA CO-PACK) Nursing Considerations

What is the generic name?

LETROZOLE AND RIBOCICLIB

What is the Trade Name for LETROZOLE AND RIBOCICLIB?

KISQALI FEMARA CO-PACK

What are the Indications for LETROZOLE AND RIBOCICLIB?

• 1 INDICATIONS AND USAGE The KISQALI ¬Æ FEMARA ¬Æ CO-PACK is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. KISQALI FEMARA CO-PACK, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1 )

References: https://open.fda.gov/